OverviewSuggest Edit

XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development, and commercialization of therapeutic antibodies based on its True Human™ proprietary technology.

XBiotech’s True Human™ antibodies are 100 percent human, derived from individuals who possess a natural immunity to certain diseases. With the discovery and clinical programs across multiple disease areas, XBiotech’s True Human™ antibodies have the potential to harness the body’s natural immunity to fight the disease with increased safety, efficacy and tolerability.

XBiotech is currently advancing a robust pipeline of antibody therapies to exceed the standards of care in oncology, inflammatory conditions and infectious diseases.

TypePublic
Founded2005
HQAustin, US
Websitexbiotech.com
Employee Ratings3

Latest Updates

Employees (est.) (Jun 2019)59(+6%)
Share Price (Jun 2019)$7.2 (-7%)

Key People/Management at XBiotech

Thorpe McKenzie

Thorpe McKenzie

Director
Jan-Paul Waldin

Jan-Paul Waldin

Director
Donald H. MacAdam

Donald H. MacAdam

Director
Show more

XBiotech Office Locations

XBiotech has an office in Austin
Austin, US (HQ)
8201 E Riverside Dr #100
Show all (1)

XBiotech Financials and Metrics

XBiotech Revenue

USD

Net income (Q2, 2019)

(5.9m)

EBIT (Q2, 2019)

(6.0m)

Market capitalization (10-Jun-2019)

259.7m

Closing stock price (10-Jun-2019)

7.2

Cash (30-Jun-2019)

44.9m
XBiotech's current market capitalization is $259.7 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

General and administrative expense

6.2m10.3m7.6m5.3m

R&D expense

31.3m42.5m26.4m15.7m

Operating expense total

37.5m52.8m34.1m21.0m

EBIT

(37.5m)(52.8m)(34.1m)(21.0m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

General and administrative expense

2.0m1.1m2.4m2.4m2.7m2.1m2.3m1.7m1.2m1.7m1.2m1.3m1.3m

R&D expense

4.4m9.7m7.8m11.2m9.8m8.2m7.4m4.9m3.0m3.9m3.9m4.5m4.7m

Operating expense total

6.4m10.8m10.2m13.6m12.5m10.3m9.7m6.6m4.2m5.6m5.1m5.8m6.0m

EBIT

(6.4m)(10.8m)10.2m(13.6m)(12.5m)(10.3m)(9.7m)(6.6m)(4.1m)(5.6m)(5.1m)(5.8m)(6.0m)
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Cash

91.1m34.3m31.8m15.8m

Current Assets

93.0m36.9m33.3m17.0m

PP&E

5.9m10.1m29.6m27.3m

Total Assets

109.4m67.1m63.0m44.3m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(37.5m)(50.7m)(33.1m)(21.1m)

Depreciation and Amortization

699.0k698.0k1.5m2.4m

Accounts Payable

840.0k(981.0k)(2.7m)(78.0k)

Cash From Operating Activities

(33.3m)(46.0m)(33.6m)(16.5m)
USDY, 2019

Financial Leverage

1 x
Show all financial metrics

XBiotech Online and Social Media Presence

Embed Graph

XBiotech News and Updates

XBiotech Announces Dr. Alice Gottlieb to Chair Upcoming Phase 2 Study of Bermekimab in Hidradenitis Suppurativa

AUSTIN, Texas, June 25, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announces that Alice Gottlieb M.D., Ph.D., will Chair the Company’s upcoming Phase II study in Hidradenitis Suppurativa (HS). Dr. Gottlieb is Medical Director of dermatology at the Mount Sinai Beth Israel Campus, and Clinical…

XBiotech Announces Public Offering of Common Shares

AUSTIN, Texas, May 30, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced that it has commenced an underwritten public offering of common shares, subject to market and other conditions.   XBiotech intends to grant the underwriter in the offering a 30-day option to purchase addit…

XBiotech Announces Enrollment Completion in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Atopic Dermatitis

AUSTIN, Texas, Oct. 05, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that it has completed enrollment in its Phase 2, open label clinical study evaluating subcutaneous administration of bermekimab in patients with moderate to severe Atopic Dermatitis (AD). XBiotech has now…

XBiotech gibt die Erteilung eines europäischen Patents zur Behandlung entzündlicher Hauterkrankungen bekannt

Erteilung eines umfassenden europäischen Patents stützt das Programm zum monoklonalen Antikörper Bermekimab für die Behandlung von Hauterkrankungen Erteilung eines umfassenden europäischen Patents stützt das Programm zum monoklonalen Antikörper Bermekimab für die Behandlung von Hauterkrankungen

XBiotech annonce l'octroi d'un brevet européen pour le traitement de maladies inflammatoires de la peau

Un brevet délivré à l’échelle européenne soutient le programme de lutte contre les maladies de la peau de XBiotech pour les anticorps monoclonaux Bermekimab Un brevet délivré à l’échelle européenne soutient le programme de lutte contre les maladies de la peau de XBiotech pour les anticorps monoclona…
Show more

XBiotech Blogs

Peter Libby, MD

Peter Libby, MD william.meady@… Tue, 07/23/2019 - 14:23 Peter Libby, MD Director Peter Libby, MD, is a cardiovascular specialist at Brigham and Women’s Hospital in Boston, Massachusetts, and holds the Mallinckrodt Professorship of Medicine at Harvard Medical Schoo…

XBiotech Adds Dr. Peter Libby, Renowned Cardiologist and Research Pioneer in Inflammation and Cardiovascular Disease, to its Corporate Board

AUSTIN, Texas , July 10, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that Peter Libby , M.D., has been appointed to the Company’s Corporate Board of Directors.  Dr. Libby has played a pioneering role in discovering how inflammation leads to cardiovascular disease. Dr.

Medical Research Council Funds Phase 2 Multi-Center Study of XBiotech’s Bermekimab in Advanced Cancer Patients

Medical Research Council (MRC) Grants Funding for Bermekimab as Part of its Support for “Outstanding Clinical Programs in the United Kingdom” AUSTIN, Texas , July 09, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that the Medical Research Council (MRC), part of UK Research and

XBiotech Wins “Commercial Real Estate Award for Industrial Development” for its Headquarters in Austin, Texas

AUSTIN, Texas , June 26, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that it is the recipient of the first place 2019 Commercial Real Estate Award for Industrial Development , chosen by the Austin Business Journal . XBiotech USA Inc.

XBiotech Added to Russell 3000® Index

AUSTIN, Texas , June 11, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the Company has been added to the preliminary list of the broad market Russell 3000 ®  Index, which will take effect after US market close on June 28 , as part of the 2019 Russell indexes

XBiotech Announces Closing of Public Offering of Common Shares

AUSTIN, Texas , June 04, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced the closing of its previously announced underwritten public offering of 4,848,485 of its common shares at a public offering price of $8.25 per share.  In addition, XBiotech has granted the underwriter a

XBiotech Frequently Asked Questions

  • When was XBiotech founded?

    XBiotech was founded in 2005.

  • Who are XBiotech key executives?

    XBiotech's key executives are Thorpe McKenzie, Jan-Paul Waldin and Donald H. MacAdam.

  • How many employees does XBiotech have?

    XBiotech has 59 employees.

  • Who are XBiotech competitors?

    Competitors of XBiotech include Aptevo Therapeutics, Geron and Aeglea Biotherapeutics.

  • Where is XBiotech headquarters?

    XBiotech headquarters is located at 8201 E Riverside Dr #100, Austin.

  • Where are XBiotech offices?

    XBiotech has an office in Austin.

  • How many offices does XBiotech have?

    XBiotech has 1 office.